TBF1.F - Canntab Therapeutics Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2019-05-31
2018-05-31
2017-12-31
2017-05-31
2016-12-31
Total Revenue
363
240
27
0
0
942
Cost of Revenue
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
Operating Expenses
Research Development
123
128
141
-
41
-
Selling General and Administrative
2,497
2,437
2,258
188
1,074
312
Total Operating Expenses
2,840
2,742
2,450
188
1,117
312
Operating Income or Loss
-2,477
-2,502
-2,423
-188
-1,117
631
Interest Expense
-
-
-
-
-
-
Total Other Income/Expenses Net
-
-
-
6
-
-111
Income Before Tax
-2,452
-2,459
-2,408
-182
-1,116
520
Income Tax Expense
-
-
-
-
-
-
Income from Continuing Operations
-2,452
-2,459
-2,408
-182
-1,116
520
Net Income
-2,452
-2,459
-2,408
-182
-1,116
520
Net Income available to common shareholders
-2,452
-2,459
-2,408
-182
-1,116
520
Reported EPS
Basic
-
-0.10
-0.11
-0.40
-0.07
1.20
Diluted
-
-0.10
-0.11
-0.40
-0.07
1.00
Weighted average shares outstanding
Basic
-
25,299
21,129
556
15,000
452
Diluted
-
25,299
21,129
556
15,000
520
EBITDA
-
-2,421
-2,372
-188
-1,115
631